US health regulator Food and Drug Administration gave approval to a generic version of Johnson & Johnson's epilepsy drug Topamax, also known as topiramate.

Topiramate has been approved for treatment of partial onset seizures.
The company said Topiramate tablets are the generic version of Topamax tablets from Ortho-McNeil Janssen Pharmaceuticals portfolio and are available in four strengths 25 mg, 50 mg, 100 mg, and 200 mg.

The Company added that these strengths of Topamax tablets have annual sales of approximately $2.5 billion in the US market.